Ajanta Explains FDA Sildenafil Action, Shares Rebound
Executive Summary
Ajanta Pharma regained some lost ground on Indian bourses after the company clarified its position on an FDA import alert against its sildenafil citrate product and reported a healthy set of earnings for the third quarter ended December 2016.
You may also be interested in...
More Indian drugs detained in EU as FTA talks progress ahead of summit
Even as the EU and India continue negotiations on a free trade agreement ahead of their next summit in February, another in transit consignment of Indian generics was seized in the EU late last year, much to the consternation of both the Indian industry and the Indian government1,2. The seizure appears to have disrupted a long quiet period of sorts on the controversial issue of controversial detentions of transiting Indian consignments of generic medicines at EU ports over alleged violations of intellectual property rights.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet